Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
Yuki Kato,1 Yasuhiro Kato,1 Yuji Minegishi,1,2 Takahiro Suzuki,1 Shinji Nakamichi,1 Masaru Matsumoto,1 Akihiko Miyanaga,1 Rintaro Noro,1 Kaoru Kubota,1 Yasuhiro Terasaki,3 Masahiro Seike,1 Akihiko Gemma1 1Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical Scho...
Enregistré dans:
Auteurs principaux: | Kato Y, Minegishi Y, Suzuki T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Terasaki Y, Seike M, Gemma A |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/42a3fb5282a946ddace0dd322e9a672c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
par: Linehan AS, et autres
Publié: (2021) -
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
par: Salkeni MA, et autres
Publié: (2021) -
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
par: Jagosky M, et autres
Publié: (2021) -
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
par: Rodallec A, et autres
Publié: (2018) -
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
par: Yurong Wang, et autres
Publié: (2021)